Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis


Q What is the efficacy of fluconazole for recurrent vulvovaginal candidiasis (VC)?

METHODS

- **Design**: randomised placebo controlled trial.
- **Allocation**: unclear.
- **Blinding**: blinded (patients and healthcare providers).
- **Follow up period**: 12 months.
- **Setting**: multiple centres in the US.

**Patients**: 307 women >18 years of age (mean age 34 y, 67% white) who had active, acute candida vaginitis (severity score ≥3), a positive result on microscopic examination of vaginal secretions, >4 episodes of candida vaginitis in the previous 12 months, and were clinically cured (severity score <3) at 14 days after receiving 3 sequential doses of fluconazole, 150 mg, at 72 hour intervals. Exclusion criteria: lack of confirmation of microscopic findings by culture, pregnancy, mixed infections or known seropositivity for HIV, or use of antifungal agents in the previous 4 weeks.

**Intervention**: a single oral dose of fluconazole, 150 mg (n=170),* or an oral placebo tablet taken weekly for 6 months (n=173).*

**Outcomes**: clinical recurrence of VC (severity score ≥3 plus vaginal cultures positive for yeast) at the end of the 6 month treatment period and at 12 months, and time to clinical and mycologic recurrence of VC.

**Patient follow up**: 373 of 387 women (96%) were included in the modified intention to treat (ITT) analysis. Efficacy analyses were based on data from 283 women (73%) for clinical recurrence at 6 months and 263 women (68%) for clinical recurrence at 1 year.

*Data on allocation status only available for 343 women included in the efficacy analysis.

**RESULTS**

Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis. In women with recurrent vulvovaginal candidiasis (VC), fluconazole reduced the rate of recurrence of VC and increased time to clinical and mycologic recurrence.

*Calculated from data in original article.

CONCLUSION

In women with recurrent vulvovaginal candidiasis (VC), fluconazole reduced the rate of recurrence of VC and increased time to clinical and mycologic recurrence.

More than half of women in the US will experience ≥1 episode of VC by the time they reach the age of 25 years, and about 5% of these women (nearly 1.3 million) will have recurrences throughout adulthood. Sobel et al investigated how to reduce recurrences in these women. To diagnose VC, women had to have symptom severity scores ≥3 (0 = absent or normal; 3 = severe) for 3 symptoms (pruritus, irritation, and burning) and 3 signs (erythema, oedema, and excoriation or fissures) as well as a positive fungal culture. Hence, a spectrum of women with mild to severe VC symptoms and signs may have been enrolled in the study. The authors refer to “clinical cure” of VC, which is perhaps more accurately referred to as “effective suppression” of symptoms and signs. It is unclear which specific symptoms and signs were present in women categorised as having “effective suppression” or “recurrence.” Also, clinicians should note that other variables commonly believed to predict VC, such as history of antibiotic and oral contraceptive use, were not associated with clinical response.

Even with this low threshold for clinical diagnosis of VC, weekly fluconazole resulted in recurrence rates of 4% (6 of 166 women) at 1 month and 9% (13 of 141 women) at 6 months. The 1 month post-treatment recurrence rate is far better than previous reports of 20% for both the usual 1 time oral dose and intravaginal medication. Better yet, this low recurrence rate was accompanied by a reassuring side effect and safety profile that persisted throughout the 12 month study. Overall, the clinical outcomes of this study are impressive and translate into a safe and convenient treatment for women with recurrent VC. Ease of access to fluconazole and cost were not addressed in this study. However, fluconazole is now available over the counter in the US. In the UK, where it remains a prescription drug, four 150 mg tablets can be purchased for about US$25 (www.drugstore.com, accessed 3 February 2005).

Gene Harkless, RN, DNSc, ANRP
University of New Hampshire
Durham, New Hampshire, USA

1 Ringdahl EN. Treatment of recurrent vulvovaginal candidiasis. Am Fam Physician 2000;61:3306–12, 3317